Literature DB >> 18974282

Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function.

Anders Viberg1, Otto Cars, Mats O Karlsson, Siv Jönsson.   

Abstract

An approach for estimation of dosing strategies based on data-derived models and assessment of the risk associated with deviation from the treatment target is presented. The work is illustrated by establishing a dosing strategy to be used for a priori individualization on the basis of renal function for the antibiotic cefuroxime. Treatment involved exposing patients to concentrations above the minimum inhibitory concentration (MIC) for 50% of the dosing interval. The risk (penalty) function incorporated both deviations from the target and the use of excess amount of drug. Dosing strategies were estimated for a target population by minimizing the risk function. The population was characterized by a population pharmacokinetic model, and distributions of CLcr and body weight were reflective of the target group. The estimated dosing strategies were assessed by evaluating population distributions of (1) percentage of dosing interval with concentrations above MIC, (2) time of drug exposure below MIC, and (3) drug administered in excess to reach the target. These distributions were generated using wild-type MIC distributions for Escherichia coli and Streptococcus pneumoniae. The authors illustrate how benefits and risks of drug treatment can be weighed quantitatively in decision-based risk functions and subsequently used in the estimation of drug dosing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974282     DOI: 10.1177/0091270008320923

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  8 in total

1.  Balancing Antibacterial Efficacy and Reduction in Renal Function to Optimise Initial Gentamicin Dosing in Paediatric Oncology Patients.

Authors:  Carolina Consuelo Llanos-Paez; Christine Staatz; Stefanie Hennig
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

2.  Blood concentrations of cefuroxime in cardiopulmonary bypass surgery.

Authors:  Daphne Bertholee; Peter G J ter Horst; Michel L Hijmering; Alexander J Spanjersberg; Wobbe Hospes; Bob Wilffert
Journal:  Int J Clin Pharm       Date:  2013-06-21

3.  Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.

Authors:  Stefanie Hennig; Joseph F Standing; Christine E Staatz; Alison H Thomson
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

4.  New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics.

Authors:  J B Bulitta; C B Landersdorfer; M Kinzig; U Holzgrabe; F Sorgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

5.  Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.

Authors:  R Bruch; C Chatelle; A Kling; B Rebmann; S Wirth; S Schumann; W Weber; C Dincer; G Urban
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

6.  Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Authors:  Elin M Svensson; Gunnar Yngman; Paolo Denti; Helen McIlleron; Maria C Kjellsson; Mats O Karlsson
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

7.  Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort.

Authors:  Sara Thønnings; Filip Jansåker; Kim Oren Gradel; Bjarne Styrishave; Jenny Dahl Knudsen
Journal:  Infect Drug Resist       Date:  2019-05-13       Impact factor: 4.003

8.  Dose banding - Weighing up benefits, risks and therapeutic failure.

Authors:  Stephen Duffull
Journal:  Br J Clin Pharmacol       Date:  2022-03-24       Impact factor: 3.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.